U.S. cancer death rates declined steadily from 2001 to 2022, including during the pandemic, driven by advances in detection and treatment. Regulatory fraud enforcement and new FDA approvals impact healthcare and insurance sectors.

The 2024 cancer report highlights declines in US cancer mortality through 2022, with 2020 pandemic-related diagnosis drops not persisting into 2021. Key insights for oncology insurers and providers.

A study reveals that advanced cancer patients on Medicare often receive aggressive treatments over supportive care, raising concerns about patient care priorities.